90% cure rate for MRSA cSSSI with J&J's ceftobiprole
US health care major Johnson & Johnson's investigational antibiotic ceftobiprole was as effective as commonly-used combination therapy in treating patients with complicated skin infections caused by a broad spectrum of bacteria, according to data presented at the 47th annual Interscience Conference on Antimicrobial Agents and Chemotherapy, held in Chicago, USA.
Ceftobiprole also was found to clinically cure more than 90% of patients who had infections caused by Staphylococcus aureus, including patients with complicated skin infections due to PVL-positive methicillin-resistant S aureus. The agent belongs to a class of antibacterial agents known as cephalosporins, which are used to treat serious infections, and was licensed from and is being co-developed with Swiss drug developer Basilea Pharmaceutica.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze